Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.53 |
| ▸ | TUBB | P07437 | 2/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Picrostegane SCHEMBL14097820 | 1.00 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14624873 | 0.90 | ACHE (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL7438626 | 0.86 | ATM (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9951919 | 0.84 | GSK3B (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5014622 | 0.80 | CYP3A4 (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14097830 | 0.80 | CYP3A4 (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Steganacin SCHEMBL14138211 | 0.76 | LMNA (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Steganacin SCHEMBL66054 | 0.76 | LMNA (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| (-)-Steganacin SCHEMBL10065023 | 0.76 | LMNA (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14625258 | 0.76 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907380-A2 | PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS | Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP (BR) | 2008-04-09 | — | — | EP | claimed |
| WO-2007009201-A2 | PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS | Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) | 2007-01-25 | — | — | WO | claimed |
| EP-1487770-B1 | FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE | COUNCIL SCIENT IND RES (IN) | 2007-12-12 | — | — | EP | disclosed |
| US-6969778-B2 | DDQ mediated one step dimerization of β-asarone or β-asarone rich Acorus calamus oil in the formation of novel neolignan | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-11-29 | — | — | US | disclosed |
| EP-1487770-A1 | FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE | Council of Scientific and Industrial Research;an Indian Reg. body incorporated under Reg. of Societies Act (Act XXI of 1860) (IN) | 2004-12-22 | — | — | EP | disclosed |
| US-20040049085-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-03-11 | — | — | US | disclosed |
| US-20030187306-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2003-10-02 | — | — | US | disclosed |
| WO-2003080551-A1 | FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049085-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | DHPS, PTGES, PTGIS | TUBB4A 1649/4885TUBB 1918/4885TUBA3C 2076/4885 |
| US-20030187306-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | DHPS, PTGES, PTGIS | TUBB4A 1649/4885TUBB 1918/4885TUBA3C 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.